首页> 外文OA文献 >HERMIONE: a randomized Phase 2 trial of MM-302 plus trastuzumab versus chemotherapy of physician’s choice plus trastuzumab in patients with previously treated, anthracycline-naïve, HER2-positive, locally advanced/metastatic breast cancer

【2h】

HERMIONE: a randomized Phase 2 trial of MM-302 plus trastuzumab versus chemotherapy of physician’s choice plus trastuzumab in patients with previously treated, anthracycline-naïve, HER2-positive, locally advanced/metastatic breast cancer

机译：HERMIONE：MM-302加曲妥珠单抗与医师选择的化疗加曲妥珠单抗的2期随机对照试验，用于先前已治疗，无蒽环类，HER2阳性，局部晚期/转移性乳腺癌的患者

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

著录项
相似文献
相关主题

著录项

作者

展开▼
作者单位

展开▼
年度 2016
总页数
原文格式 PDF
正文语种
中图分类

相似文献

外文文献
中文文献
专利

1. HERMIONE: a randomized Phase 2 trial of MM-302 plus trastuzumab versus chemotherapy of physician’s choice plus trastuzumab in patients with previously treated, anthracycline-na?ve, HER2-positive, locally advanced/metastatic breast cancer [J] . Kathy Miller, Javier Cortes, Sara A. Hurvitz, BMC Cancer . 2016,第1期

机译：HERMIONE：MM-302联合曲妥珠单抗与医师选择的化学疗法加曲妥珠单抗在先前治疗过的蒽环类初治，HER2阳性，局部晚期/转移性乳腺癌患者中进行的随机2期试验
2. A randomized, open-label, Phase III trial of pertuzumab retreatment in HER2-positive locally advanced/metastatic breast cancer patients previously treated with pertuzumab, trastuzumab and chemotherapy: the Japan Breast Cancer Research Group-M05 PRECIOUS study [J] . Yamamoto Yutaka, Iwata Hiroji, Ueno Takayuki, Japanese journal of clinical oncology. . 2018,第9期

机译：在Her2阳性局部晚期/转移性乳腺癌患者中，Hertuzumab患者的随机开放标签，腹部疗法试验，曲妥珠单抗和化疗：日本乳腺癌研究组-M05珍贵研究
3. Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parallel HER2-negative cohort. [J] . Gianni L, Eiermann W, Semiglazov V, The Lancet . 2010,第9712期

机译：对于HER2阳性的局部晚期乳腺癌患者，使用曲妥珠单抗的新辅助化疗联合曲妥珠单抗辅助与单独的新辅助化疗相比（NOAH试验）：一项平行HER2阴性队列的随机对照优势试验。
4. Elevated WBP2 Expression in HER2-Positive Breast Cancers Correlates with Sensitivity to Trastuzumab-Based Neo-Adjuvant Therapy: A Retrospective and Multicentric Study [C] . Yoon Pin Lim International Molecular Medicine Tri-Conference. . 2019

机译：HER2阳性乳腺癌中的WBP2表达升高与基于曲妥珠单抗的新辅助治疗的敏感性相关：回顾性和多中心研究
5. A phase Ib study of safety and pharmacokinetics of trastuzumab emtansine and pertuzumab in Japanese patients with HER2-positive metastatic breast cancer [D] . NOGUCHI, Emi 2019

机译：Ib期研究曲妥珠单抗氨丹宁和帕妥珠单抗在日本HER2阳性转移性乳腺癌患者中的安全性和药代动力学
6. HERMIONE: a randomized Phase 2 trial of MM-302 plus trastuzumab versus chemotherapy of physician’s choice plus trastuzumab in patients with previously treated anthracycline-naïve HER2-positive locally advanced/metastatic breast cancer [O] . Kathy Miller, Javier Cortes, Sara A. Hurvitz, 2016

机译：HERMIONE：MM-302联合曲妥珠单抗与医师选择的化学疗法加曲妥珠单抗在之前治疗过无蒽环类HER2阳性局部晚期/转移性乳腺癌的患者中进行的随机2期试验
7. A randomized, open-label, Phase III trial of pertuzumab retreatment in HER2-positive locally advanced/metastatic breast cancer patients previously treated with pertuzumab, trastuzumab and chemotherapy: the Japan Breast Cancer Research Group-M05 PRECIOUS study [O] . Yutaka Yamamoto, Hiroji Iwata, Takayuki Ueno, 2018

机译：在Her2-阳性局部晚期/转移性乳腺癌患者中，Hertuzumab患者的随机开放标签，腹部疗法试验，先前用Pertuzumab，Trastuzumab和化疗治疗：日本乳腺癌研究组-M05珍贵研究

HERMIONE: a randomized Phase 2 trial of MM-302 plus trastuzumab versus chemotherapy of physician’s choice plus trastuzumab in patients with previously treated, anthracycline-naïve, HER2-positive, locally advanced/metastatic breast cancer

著录项

相似文献

相关主题

期刊订阅